Gleason Score 3+4=7 Prostate Cancer with Minimal Pattern 4 Identified in Prostate Needle Biopsy Barely has Worse Pathological Outcomes

被引：0
|
作者：
Serrano, Antonio [1 ]
Melamed, Jonathan [2 ]
Ren, Qinghu [3 ]
Huang, Hongying [1 ]
Park, Kyung [1 ]
Flaifel, Abdallah [4 ]
Deng, Fangming [5 ]
机构：
[1] NYU Langone Hlth, New York, NY USA
[2] NYU, New York, NY USA
[3] NYU, Langone Med Ctr, New York, NY USA
[4] NYU, Sch Med, New York, NY USA
[5] NYU, Med Ctr, New York, NY 10016 USA
来源：
MODERN PATHOLOGY | 2020年 / 33卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1011
引用
收藏
页码：969 / 971
页数：3
相关论文
共 50 条
  • [21] Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3+4 prostate cancer
    Gondo, Tatsuo
    Poon, Bing Ying
    Matsumoto, Kazuhiro
    Bernstein, Melanie
    Sjoberg, Daniel D.
    Eastham, James A.
    BJU INTERNATIONAL, 2015, 115 (01) : 81 - 86
  • [22] Quantifying Gleason Pattern 4 Prostate Cancer in Prostate Needle Biopsy: An Interobserver Reproducibility Study
    Li, Jianhong
    Li, Jianbo
    Amin, Ali
    Bhalla, Ritu
    Das, Kasturi
    Deng, Fang-Ming
    Lee, Peng
    Matoso, Andres
    Melamed, Jonathan
    Mendrinos, Savvas
    Tian, Wei
    Yaskiv, Oksana
    Shah, Rajal
    Zhou, Ming
    MODERN PATHOLOGY, 2016, 29 : 246A - 246A
  • [23] Increasing trend of utilising active surveillance for Gleason Score 7 (3+4) prostate cancer
    Bernardino, Rui
    Sayyid, Rashid K.
    Leao, Ricardo
    Zlotta, Alexandre R.
    van Der Kwast, Theodorus
    Klotz, Laurence
    Fleshner, Neil E.
    BJU INTERNATIONAL, 2023, 132 (06) : 638 - 640
  • [24] Quantifying Gleason Pattern 4 Prostate Cancer in Prostate Needle Biopsy: An Interobserver Reproducibility Study
    Li, Jianhong
    Li, Jianbo
    Amin, Ali
    Bhalla, Ritu
    Das, Kasturi
    Deng, Fang-Ming
    Lee, Peng
    Matoso, Andres
    Melamed, Jonathan
    Mendrinos, Savvas
    Tian, Wei
    Yaskiv, Oksana
    Shah, Rajal
    Zhou, Ming
    LABORATORY INVESTIGATION, 2016, 96 : 246A - 246A
  • [25] Relation of percentage Gleason grade 4 and cribriform/intraductal growth in Gleason score 3+4=7 prostate cancer biopsies
    van Leenders, G.
    Kweldam, C.
    Kummerlin, I.
    Nieboer, D.
    Bangma, C.
    van der Kwast, T.
    Steyerberg, E.
    Roobol, M.
    VIRCHOWS ARCHIV, 2016, 469 : S14 - S14
  • [26] Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3+4=7 Prostate Cancer Diagnosed at Biopsy
    Lim, Christopher S.
    McInnes, Matthew D. F.
    Flood, Trevor A.
    Breau, Rodney H.
    Morash, Christopher
    Thornhill, Rebecca E.
    Schieda, Nicola
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2017, 208 (05) : 1037 - 1044
  • [27] Using active surveillance in biopsy proven Gleason 3+4 prostate cancer
    Wong, Lih-Ming
    Tang, Vincent
    Corcoran, Niall
    Costello, Anthony
    BJU INTERNATIONAL, 2015, 116 : 17 - 18
  • [28] EFFECT OF TUMOR VOLUME AND PRESENCE OF GLEASON PATTERN 3 IN PROSTATE CANCER PATIENTS WITH GLEASON SCORE 8 ON PROSTATE NEEDLE BIOPSY
    Ginsburg, Kevin
    Silverman, Michael
    Livingstone, Joan
    Smith, Daryn
    Heilbrun, Lance
    Cher, Michael
    JOURNAL OF UROLOGY, 2018, 199 (04): : E705 - E705
  • [29] Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3+4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance
    Gearman, Derek J.
    Morlacco, Alessandro
    Cheville, John C.
    Rangel, Laureano J.
    Karnes, R. Jeffrey
    JOURNAL OF UROLOGY, 2018, 199 (05): : 1188 - 1195
  • [30] Cases Having a Gleason Score 3+4=7 With <5% of Gleason Pattern 4 in Prostate Needle Biopsy Show Similar Failure-free Survival and Adverse Pathology Prevalence to Gleason Score 6 Cases in a Radical Prostatectomy Cohort
    Sato, Shun
    Kimura, Takahiro
    Yorozu, Takashi
    Onuma, Hajime
    Iwatani, Kosuke
    Egawa, Shin
    Ikegami, Masahiro
    Takahashi, Hiroyuki
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2019, 43 (11) : 1560 - 1565
12345